Fewer than a tenth of people that would benefit from GLP-1 drugs like Wegovy have access to them, states the World Health Organization as it issues its inaugural advice on the medications.
Considering in excess of 1,000,000,000 people worldwide now classified as obese, it is urging more widespread and fairer availability to these injectable treatments.
Based on projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"The new guidance affirms that obesity is a lifelong illness that can be addressed with holistic and continuous support," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are major barriers to universal availability to the treatments that can aid individuals in losing considerable body mass, explains the organization.
Skinny Jab Scarcity
Even under the present best projected case, the manufacturing of these medications might only reach around 100 million people – under 10% of eligible patients, as stated by the WHO.
The advice urges governments and firms to widen access, via approaches like patent sharing.
A patent on a key compound – the core ingredient of a leading brand – is set to lapse in a number of nations in 2026.
How Obesity Drugs Function
These medications imitate a natural hormone to delay gastric emptying, suppress the appetite and enhance satiety so people eat less.
People usually start to lose weight in the initial weeks of commencing the regular doses.
Studies suggests people may regain a significant portion a year later of stopping the treatment, because their normal appetite return.
To be overweight or obese raises your risk for experiencing health problems, such as type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.
Obesity impacts people in all nations and was associated with over three and a half million deaths worldwide in 2024, according to the health agency.
